CYP2C19 genotype testing in the EU >>>>>>>>5 Mar 2026 13:16
A.I.
CYP2C19 genotype testing in the European Union (EU) and the UK is gaining momentum as a crucial tool for personalized medicine, particularly for guiding the use of the antiplatelet drug clopidogrel after ischaemic stroke, transient ischaemic attack (TIA), or percutaneous coronary intervention (PCI). The test identifies genetic variants (such as *2, *3, and *17) that affect how a patient metabolizes medication.
Key Aspects of CYP2C19 Testing in Europe
Clinical Application (Clopidogrel): In European populations, approximately 15% carry the loss-of-function (LOF) allele CYP2C19*2. For these "intermediate" or "poor" metabolizers, clopidogrel is less effective, increasing the risk of further strokes or heart attacks.
Regulatory Status & Adoption: The Genedrive® CYP2C19 ID Kit received CE-certification under the European In Vitro Diagnostics Regulation (IVDR) in May 2025, enabling its use for rapid point-of-care testing in the EU.
NICE Guidelines (UK Focus): The National Institute for Health and Care Excellence (NICE) in the UK (Guidance DG59, July 2024) recommends CYP2C19 testing to guide clopidogrel use after ischaemic stroke or TIA. This is considered a cost-effective use of resources.
Alternative Therapies: Based on test results, physicians may choose alternative antiplatelet therapies like ticagrelor or prasugrel for patients with CYP2C19 loss-of-function alleles.
Evidence Basis: Large European studies, such as the 'PREPARE' study and the 'POPular Genetics' trial, have demonstrated the effectiveness of pharmacogenomic testing in reducing adverse cardiovascular events.
Other Medications: Beyond clopidogrel, the European Medicines Agency (EMA) requires or suggests CYP2C19 genotyping for other drugs, such as mavacamten (used for obstructive hypertrophic cardiomyopathy) and siponimod (requiring CYP2C9, but also relevant in wider P450 metabolism).
Current Status
While recommended by guidelines, routine implementation varies across different EU countries. The shift toward rapid, point-of-care testing (results in <1 hour) is addressing the need for immediate, actionable results in emergency clinical settings, rather than relying on slower, centralized lab services.
Sign In
Follow the stocks
